The E2 ubiquitin-conjugating enzyme UbcH5c: an emerging target in cancer and immune disorders.
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
16 Sep 2020
16 Sep 2020
Historique:
received:
14
04
2020
revised:
14
07
2020
accepted:
10
09
2020
pubmed:
19
9
2020
medline:
19
9
2020
entrez:
18
9
2020
Statut:
aheadofprint
Résumé
Ubiquitination is a crucial post-translational modification (PTM) of proteins and regulates their stabilities and activities, thereby modulating multiple signaling pathways. UbcH5c, a member of the UbcH5 ubiquitin-conjugating enzyme (E2) protein family, engages in the ubiquitination of dozens of proteins and regulates nuclear factor kappa-B (NF-κB), p53 tumor suppressor, and several other essential signaling pathways. UbcH5c has been reported to be abnormally expressed in human cancer and immune disorders and is involved in the initiation and progression of these diseases. In this review, we mainly focus on UbcH5c structure, activity, signaling pathways, and its relevance to cancer and immune disorders. We end by integrating all known factors relating to UbcH5c inhibition as a potential cancer therapy method, and discuss associated challenges.
Identifiants
pubmed: 32947046
pii: S1359-6446(20)30369-X
doi: 10.1016/j.drudis.2020.09.015
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.